Benzinga · Aug 14, 2026
Replimune Group Files Shelf Prospectus For Offering; Size Not Disclosed
-SEC Filing
RE
NASDAQ · REPL
Replimune Group, Inc.
Healthcare · Biotechnology
$14.05
Up+$0.72 (+5.12%)
Updated Aug 21, 2026, 9:10 PM
SID Score
6.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 774.6M
- P/E ratio
- -3.23
- Dividend yield
- 0.00%
- 52-week range
- $1.50 – $15.71
- Volume
- 4.3M
- Avg. volume
- 5.08M
Price performance
REPL price history
1M range · 20 trading sessions · Daily adjusted prices
REPL closed at $14.05 after 20 trading sessions, up 34.32% for the selected period.
- Last close
- $14.05
- Period change
- +34.32%
- Period low
- $5.35
- Period high
- $15.58
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $14.55 | $14.765 | $13.92 | $14.05 | 4.3M |
| Aug 19, 2026 | $15.17 | $15.64 | $14.73 | $14.81 | 3.44M |
| Aug 18, 2026 | $14.60 | $15.615 | $14.50 | $15.58 | 2.25M |
| Aug 17, 2026 | $14.65 | $14.69 | $14.05 | $14.63 | 3.74M |
| Aug 14, 2026 | $15.19 | $15.39 | $14.685 | $14.97 | 2.4M |
| Aug 13, 2026 | $15.00 | $15.705 | $14.98 | $15.19 | 3.22M |
| Aug 12, 2026 | $13.62 | $15.68 | $13.62 | $15.24 | 8.27M |
| Aug 11, 2026 | $13.755 | $14.14 | $13.20 | $13.65 | 4.77M |
| Aug 10, 2026 | $12.64 | $14.12 | $12.27 | $13.67 | 8.86M |
| Aug 7, 2026 | $13.00 | $13.40 | $11.42 | $12.06 | 8.91M |
| Aug 6, 2026 | $11.78 | $13.90 | $11.58 | $12.86 | 7.28M |
| Aug 5, 2026 | $11.96 | $12.35 | $11.50 | $11.83 | 2.86M |
| Aug 4, 2026 | $12.67 | $13.86 | $11.50 | $11.92 | 6.09M |
| Aug 3, 2026 | $10.995 | $12.60 | $10.13 | $11.91 | 11.77M |
| Jul 31, 2026 | $11.379 | $12.50 | $9.43 | $11.20 | 33.63M |
| Jul 29, 2026 | $5.25 | $5.57 | $4.7648 | $5.41 | 14.3M |
| Jul 28, 2026 | $6.61 | $6.62 | $5.135 | $5.35 | 24.02M |
| Jul 27, 2026 | $8.685 | $9.15 | $7.37 | $8.63 | 8.46M |
| Jul 24, 2026 | $10.30 | $10.375 | $9.65 | $9.70 | 3.27M |
| Jul 23, 2026 | $10.71 | $10.98 | $10.27 | $10.46 | 3.79M |
Latest REPL news
The latest Smart Investors Daily articles mentioning REPL.
Stock researchCompany · Overview
REPL research
Overview
Company profile and research snapshot.
Company profile
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.67
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 7, 2026 | Wedbush | Outperform | — |
| Aug 4, 2026 | Leerink Partners | Outperform | — |
| Jul 31, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 31, 2026 | Wedbush | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Replimune Group Q1 EPS $(0.72) Beats $(0.73) Estimate
Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 24.21 percent increase over losses of $(0.95) per share from
Benzinga · Aug 10, 2026
Replimune Prices ~$150M Underwritten Offering Of 9,701,490 Shares And Warrants At $12.06 Per Unit
The aggregate gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering
Benzinga · Aug 7, 2026
Wedbush Upgrades Replimune Group to Outperform, Raises Price Target to $19
Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform and raises the price target from $12 to $19.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
